Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11883-020-00884-2 http://scihub22266oqcxt.onion/10.1007/s11883-020-00884-2 32870376!7459268!32870376     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Atheroscler+Rep 2020 ; 22 (11): 64 Nephropedia Template TP {{tp|p=32870376|t=2020. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia |pdf=|usr=}}{{32870376}} gab.com Text The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia JO: Curr Atheroscler Rep http://www.kidney.de/pget.php?&tw=1&pmid=32870376 #FOAvip PURPOSE OF REVIEW: Statins are first-line therapy for lowering low-density lipoprotein (LDL) cholesterol in familial hypercholesterolemia (FH), particularly in heterozygous patients. We review advances and new questions on the use of statins in FH. RECENT FINDINGS: Cumulative evidence from registry data and sub-analyses of clinical trials mandates the value of statin therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in FH. Statins are safe in children and adolescents with FH, with longer term cardiovascular benefits. The potentially toxic effects of statins in pregnancy need to be considered, but no association has been reported in prospective cohort studies with birth defects. There is no rationale for discontinuation of statins in elderly FH unless indicated by adverse events. FH is undertreated, with > 80% of statin-treated FH patients failing to attain LDL cholesterol treatment targets. This may relate to adherence, tolerability, and genetic differences in statin responsiveness. Statin treatment from childhood may reduce the need for stringent cholesterol targets. Combination of statins with ezetimibe and PCSK9 inhibitors significantly improves the efficacy of treatment. Whether statin use could improve the clinical course of FH patients with COVID-19 and other respiratory infections remains an unsolved issue for future research. Statins are the mainstay for primary and secondary prevention of ASCVD in FH. Sustained long-term optimal statin treatment from an early age can effectively prevent ASCVD over decades of life. Despite their widespread use, statins merit further investigation in FH. Twit Text FOAVip The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia ????Curr Atheroscler Rep http://www.kidney.de/pget.php?&tw=1&pmid=32870376 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32870376 #FOAvip English Wikipedia <ref>{{Cite pmid|32870376}}</ref> The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia #MMPMID32870376 Pang J; Chan DC; Watts GF Curr Atheroscler Rep 2020[Sep]; 22 (11): 64 PMID32870376show ga PURPOSE OF REVIEW: Statins are first-line therapy for lowering low-density lipoprotein (LDL) cholesterol in familial hypercholesterolemia (FH), particularly in heterozygous patients. We review advances and new questions on the use of statins in FH. RECENT FINDINGS: Cumulative evidence from registry data and sub-analyses of clinical trials mandates the value of statin therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in FH. Statins are safe in children and adolescents with FH, with longer term cardiovascular benefits. The potentially toxic effects of statins in pregnancy need to be considered, but no association has been reported in prospective cohort studies with birth defects. There is no rationale for discontinuation of statins in elderly FH unless indicated by adverse events. FH is undertreated, with > 80% of statin-treated FH patients failing to attain LDL cholesterol treatment targets. This may relate to adherence, tolerability, and genetic differences in statin responsiveness. Statin treatment from childhood may reduce the need for stringent cholesterol targets. Combination of statins with ezetimibe and PCSK9 inhibitors significantly improves the efficacy of treatment. Whether statin use could improve the clinical course of FH patients with COVID-19 and other respiratory infections remains an unsolved issue for future research. Statins are the mainstay for primary and secondary prevention of ASCVD in FH. Sustained long-term optimal statin treatment from an early age can effectively prevent ASCVD over decades of life. Despite their widespread use, statins merit further investigation in FH. |*Hyperlipoproteinemia Type II/drug therapy/epidemiology[MESH] |*Medication Therapy Management[MESH] |Anticholesteremic Agents/classification/pharmacology[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Cardiovascular Diseases/epidemiology/prevention & control[MESH] |Coronavirus Infections/*epidemiology[MESH] |Humans[MESH] |Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*epidemiology[MESH]The Knowns and Unknowns of Contemporary Statin Therapy for Familial H(epmc).pdf DeepDyve Pubget Overpricing